ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Summary

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Bladder Carcinoma
• Ureter Carcinoma
• Renal Pelvis Carcinoma
• Non-small Cell Lung Cancer
• Invasive Breast Carcinoma
• Cutaneous Melanoma
• Esophageal Carcinoma
• Gastroesophageal Junction Carcinoma
• Gastric Adenocarcinoma
• Pancreatic Adenocarcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Epithelial Ovarian Carcinoma
• Fallopian Tube Carcinoma
• Endometrial Carcinoma
• Renal Cell Carcinoma
• Rectal Adenocarcinoma
• Colon Adenocarcinoma

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Guardant Health, Inc.

Last updated on ClinicalTrials.gov

September 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites